Сывороточные белки как предикторы развития химиоиндуцированной полинейропатии

Введение. Развитие полинейропатии на фоне применения цитотоксических препаратов является частым неврологическим осложнением, которое может значительно ухудшить качество жизни пациентов и ограничить возможности использования химиотерапии. Трудности в прогнозировании проявлений и тяжести неврологических осложнений обусловлены множеством факторов, включая индивидуальные особенности пациента, тип и дозу применяемого препарата, а также наличие сопутствующих заболеваний. В последние годы внимание исследователей сосредоточилось на выявлении сывороточных биомаркеров, которые могут помочь в ранней диагностике и мониторинге химиоиндуцированной полинейропатии. Понимание их роли в развитии полинейропатииможетоткрытьновыевозможностидляразработкистратегийпрофилактикиилеченияданногоосложнения, что, в свою очередь, может повысить эффективность лечения и улучшить качество жизни пациентов. Данный обзор посвящен биомаркерам и их клиническому значению в развитии химиоиндуцированной полинейропатии.

Цель исследования – анализ и обобщение современных представлений о сывороточных биологических маркерах химиоиндуцированной полинейропатии на основании данных литературы.

Материалы и методы. Поиск литературы проводили с использованием баз данных PubMed и Medline.В анализ включали систематические обзоры, публикации оригинальных исследований и метаанализы в период с 2000 по 2023 г.

Результаты. За последние десятилетия появилось новое понимание роли биомаркеров в развитии химиоиндуцированной полинейропатии, среди которых наиболее специфичными являются нейрофиламенты. Использование доступных и чувствительных методик измерения концентрации биомаркеров позволит на ранней стадии прогнозировать и предотвращать развитие данного осложнения.

Заключение.Анализданныхлитературыпоказалвысокуюзначимостьбиомаркеровприповрежденииструктур периферической нервной системы, что может в ближайшем будущем отразиться на тактике ведения онкологических пациентов и, в свою очередь, улучшит качество их жизни.

1. Zedan A.H., Vilholm O.J. Chemotherapy-induced polyneuropathy: major agents and assessment by questionnaires. Basic Clin Pharmacol Toxicol 2014;115(2):193–200. DOI:10.1111/bcpt.12262

2. Seretny M., Currie G.L., Sena E.S. et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain 2014;155(12):2461–70. DOI: 10.1016/j.pain.2014.09.020

3. Cavaletti G., Alberti P., Frigeni B. et al. Chemotherapy-induced neuropathy. Curr Treat Options Neurol 2011;13(2):180–90. DOI:10.1007/s11940-010-0108-3

4. Choi J., Kong K., Mozaffar T., Holcombe R.F. Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer. Anticancer Drugs 2006;17(1):103–5. DOI: 10.1097/01.cad.0000185185.64980.70

5. Quasthoff S., Hartung H.P. Chemotherapy-induced peripheral neuropathy. J Neurol 2002;249(1):9–17. DOI: 10.1007/pl00007853

6. Colvin L.A. Chemotherapy-induced peripheral neuropathy (CIPN): where are we now? Pain 2019;160:S1. DOI: 10.1097/j.pain.0000000000001540

7. Loprinzi C.L., Lacchetti C., Bleeker J. et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325–48. DOI:10.1200/JCO.20.01399

8. Hertz D.L., Childs D.S., Park S.B. et al. Patient-centric decision framework for treatment alterations in patients with chemotherapy-induced peripheral neuropathy (CIPN). Cancer Treat Rev 2021;99:102241. DOI: 10.1016/j.ctrv.2021.102241

9. Delaby C., Alcolea D., Carmona-Iragui M. et al. Differential levels of neurofilament light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders. Sci Rep 2020;10(1):9161. DOI: 10.1038/s41598-020-66090-x

10. Kim S-H., Choi M.K., Park N.Y. et al. Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy. Sci Rep 2020;10(1):7995. DOI:10.1038/s41598-020-64511-5

11. Huehnchen P., Schinke C., Bangemann N. et al. Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy. JCI Insight 2022;7(6):e154395. DOI: 10.1172/jci.insight.154395

12. Kim S.H., Kim K.H., Hyun J.W. et al. Blood neurofilament light chain as a biomarker for monitoring and predicting paclitaxelinduced peripheral neuropathy in patients with gynecological cancers. Front Oncol 2022;12:942960. DOI: 10.3389/fonc.2022.942960

13. Meregalli C., Fumagalli G., Alberti P. et al. Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of chemotherapy-induced peripheral neurotoxicity. Arch Toxicol 2020;94(7):2517–22. DOI:10.1007/s00204-020-02755-w

14. Burgess B.L., Cho E., Honigberg L. Neurofilament light as a predictive biomarker of unresolved chemotherapy-induced peripheral neuropathy in subjects receiving paclitaxel and carboplatin. Sci Rep 2022;12(1):15593. DOI: 10.1038/s41598-022-18716-5

15. Romano R., Del Fiore V.S., Bucci C. Role of the intermediate filament protein peripherin in health and disease. Int J Mol Sci 2022;23(23):15416. DOI:10.3390/ijms232315416

16. Yuan A., Sasaki T., Kumar A. et al. Peripherin is a subunit of peripheral nerve neurofilaments: implications for differential vulnerability of CNS and peripheral nervous system axons. J Neurosci 2012;32(25):8501–8. DOI: 10.1523/JNEUROSCI.1081-12.2012

17. Keddie S., Smyth D., Keh R.Y.S. et al. Peripherin is a biomarker of axonal damage in peripheral nervous system disease. Brain 2023;146(11):4562–73. DOI:10.1093/brain/awad234

18. Meregalli C., Bonomo R., Cavaletti G., Carozzi V.A. Blood molecular biomarkers for chemotherapy-induced peripheral neuropathy: from preclinical models to clinical practice. Neurosci Lett 2021;749:135739. DOI: 10.1016/j.neulet.2021.135739

19. Youk J., Kim Y.S., Lim J.A. et al. Depletion of nerve growth factor in chemotherapy-induced peripheral neuropathy associated with hematologic malignancies. PLoS One 2017;12(8):e0183491. DOI: 10.1371/journal.pone.0183491

20. Omar N.A., Kumar J., Teoh S.L. Neurotrophin-3 and neurotrophin-4: The unsung heroes that lies behind the meninges. Neuropeptides 2022;92:102226. DOI: 10.1016/j.npep.2022.102226

21. Aloe L, Rocco ML, Bianchi P, Manni L. Nerve growth factor: from the early discoveries to the potential clinical use. J Transl Med 2012;10:239. DOI: 10.1186/1479-5876-10-239

22. De Santis S., Pace A., Bove L. et al. Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. Clin Cancer Res 2000;6(1):90–5. PMID: 10656436

23. Velasco R., Navarro X., Gil-Gil M. et al. Neuropathic pain and nerve growth factor in chemotherapy-induced peripheral neuropathy: prospective clinical-pathological study. J Pain Symptom Manage 2017;54(6):815–25. DOI: 10.1016/j.jpainsymman.2017.04.021

24. Wang X., Ratnam J., Zou B. et al. TrkB signaling is required for both the induction and maintenance of tissue and nerve injury-induced persistent pain. J Neurosci 2009;29(17):5508–15. DOI: 10.1523/JNEUROSCI.4288-08.2009

25. Szudy-Szczyrek A., Mlak R., Bury-Kamińska M. et al. Serum brain-derived neurotrophic factor (BDNF) concentration predicts polyneuropathy and overall survival in multiple myeloma patients. Br J Haematol 2020;191(1):77–89. DOI: 10.1111/bjh.16862

26. Azoulay D., Giryes S., Nasser R. et al. Prediction of chemotherapy-induced peripheral neuropathy in patients with lymphoma and myeloma: the roles of brain-derived neurotropic factor protein levels and A gene polymorphism. J Clin Neurol 2019;15(4):511–6. DOI: 10.3988/jcn.2019.15.4.511

27. Tonyan S., Pospelova M., Krasnikova V. et al. Neurotrophin-3 (NT-3) as a potential biomarker of the peripheral nervous system damage following breast cancer treatment. Pathophysiology 2023;30(2):110–22. DOI: 10.3390/pathophysiology30020010

28. Wilson-Gerwing T.D., Dmyterko M.V., Zochodne D.W. et al. Neurotrophin-3 suppresses thermal hyperalgesia associated with neuropathic pain and attenuates transient receptor potential vanilloid receptor-1 expression in adult sensory neurons. J Neurosci 2005;25(3):758–67. DOI: 10.1523/JNEUROSCI.3909-04.2005

29. Hernández-Echeagaray E. Neurotrophin-3 modulates synaptic transmission. Vitam Horm 2020;114:71–89. DOI: 10.1016/bs.vh.2020.04.008

30. Gandhi R., Ryals J.M., Wright D.E. Neurotrophin-3 reverses chronic mechanical hyperalgesia induced by intramuscular acid injection. J Neurosci 2004;24(42):9405–13. DOI: 10.1523/JNEUROSCI.0899-04.2004

31. Wilson-Gerwing T.D., Stucky C.L., McComb G.W., Verge V.M. Neurotrophin-3 significantly reduces sodium channel expression linked to neuropathic pain states. Exp Neurol 2008;213(2):303–14. DOI: 10.1016/j.expneurol.2008.06.002

32. Sahenk Z., Nagaraja H.N., McCracken B.S. et al. NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients. Neurology 2005;65(5):681–9. DOI: 10.1212/01.wnl.0000171978.70849.c5

33. Chaudhry V., Giuliani M., Petty B.G. et al. Tolerability of recombinant-methionyl human neurotrophin-3 (r-metHuNT3) in healthy subjects. Muscle Nerve 2000;23(2):189–92. DOI: 10.1002/(sici)1097-4598(200002)23:23.0.co;2-8

34. Xu X., Song L., Li Y. et al. Neurotrophin-3 promotes peripheral nerve regeneration by maintaining a repair state of Schwann cells after chronic denervation via the TrkC/ ERK/c-Jun pathway. J Transl Med 2023;21(1):733. DOI:10.1186/s12967-023-04609-2

35. Srejovic I., Selakovic D., Jovicic N. et al. Galectin-3: roles in neurodevelopment, neuroinflammation, and behavior. Biomolecules 2020;10(5):798. DOI:10.3390/biom10050798

36. Burguillos M.A., Svensson M., Schulte T. et al. Microgliasecreted galectin-3 acts as a toll-like receptor 4 ligand and contributes to microglial activation. Cell Rep 2015;10(9):1626–38. DOI: 10.1016/j.celrep.2015.02.012

37. Ma Z., Han Q., Wang X. et al. Galectin-3 inhibition is associated with neuropathic pain attenuation after peripheral nerve injury. PLoS One 2016;11(2):e0148792. DOI: 10.1371/journal.pone.0148792

38. Koyanagi M., Imai S., Matsumoto M. et al. Pronociceptive roles of Schwann cell-derived galectin-3 in taxane-induced peripheral neuropathy. Cancer Res 2021;81(8):2207–19. DOI: 10.1158/0008-5472.CAN-20-2799

39. Sommer C., Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett 2004;361(1-3):184–7. DOI: 10.1016/j.neulet.2003.12.007

40. Tofaris G.K., Patterson P.H., Jessen K.R., Mirsky R. Denervated Schwann cells attract macrophages by secretion of leukemia inhibitory factor (LIF) and monocyte chemoattractant protein-1 in a process regulated by interleukin-6 and LIF. J Neurosci 2002;22(15):6696–703. DOI: 10.1523/JNEUROSCI.22-15-06696.2002

41. Wang X.M., Lehky T.J. Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine 2012;59(1):3–9. DOI: 10.1016/j.cyto.2012.03.027

42. Illias A.M., Gist A.C., Zhang H. et al. Chemokine CCL2 and its receptor CCR2 in the dorsal root ganglion contribute to oxaliplatin-induced mechanical hypersensitivity. Pain 2018; 159(7):1308–16. DOI: 10.1097/j.pain.0000000000001212

43. Schäfers M., Brinkhoff J., Neukirchen S. et al. Combined epineurial therapy with neutralizing antibodies to tumor necrosis factor-alpha and interleukin-1 receptor has an additive effect in reducing neuropathic pain in mice. Neurosci Lett 2001;310(2-3): 113–6. DOI: 10.1016/s0304-3940(01)02077-8

44. Liu C.C., Lu N., Cui Y. et al. Prevention of paclitaxel-induced allodynia by minocycline: effect on loss of peripheral nerve fibers and infiltration of macrophages in rats. Mol Pain 2010;6:76. DOI: 10.1016/s0304-3940(01)02077-8

45. Boyette-Davis J., Dougherty P.M. Protection against oxaliplatininduced mechanical hyperalgesia and intraepidermal nerve fiber loss by minocycline. Exp Neurol 2011;229(2):353–7. DOI: 10.1016/j.expneurol.2011.02.019

46. Castello L.M., Raineri D., Salmi L. et al. Osteopontin at the crossroads of inflammation and tumor progression. Mediators Inflamm 2017;2017:4049098. DOI: 10.1155/2017/4049098

47. Pizzamiglio C., Ripellino P., Prandi P. et al. Nerve conduction, circulating osteopontin and taxane-induced neuropathy in breast cancer patients. Neurophysiol Clin 2020;50(1):47–54. DOI: 10.1016/j.neucli.2019.12.001

48. Lund S.A., Wilson C.L., Raines E.W. et al. Osteopontin mediates macrophage chemotaxis via α4 and α9 integrins and survival via the α4 integrin. J Cell Biochem 2013;114(5):1194–202. DOI:10.1002/jcb.24462

49. Hu S., Huang K.M., Adams E.J. et al. Recent developments of novel pharmacologic therapeutics for prevention of chemotherapy-induced peripheral neuropathy. Clin Cancer Res 2019;25(21):6295–301. DOI: 10.1158/1078-0432.CCR-18-2152